Amira Pharmaceuticals - Product Pipeline Review - Q4 2010

Amira Pharmaceuticals - Product Pipeline Review - Q4 2010 provides data on the company's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
It also gives a complete picture of the company's future therapy areas of focus.
This report is built using data and information sourced from proprietary databases, primary and secondary research using the company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by a team of industry experts.

Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases

Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist. If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.

"We believe the pre-clinical data obtained to date for AM152 demonstrate characteristics which warrant further studies in humans to determine its potential utility in various fibrotic diseases," said Isabelle DeArmond, Vice President, Clinical Development. "The safety and pharmacokinetic data obtained from Phase 1 studies are an important first step in the clinical investigation of this program."

Added Bob Baltera, Chief Executive Officer, "We are extremely excited to reach this point with our LPA1 program. There have recently been numerous papers published describing the novel biology of the LPA1 receptor and how it relates to abnormal fibrotic processes. We have worked hard to develop this program and look forward to learning more about this potential therapeutic candidate in a clinical setting."

While there are no LPA1 selective antagonists approved for therapeutic use, there is a strong scientific rationale for this target to be a novel treatment in various fibrotic diseases, including scleroderma and idiopathic pulmonary fibrosis.

Amira Pharmaceuticals to Present at Montgomery Healthcare Conference

Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease, announced today that Robert Baltera, Chief Executive Officer, will present a company overview at the Montgomery Healthcare Conference 2009 in Menlo Park, Calif., today.

Amira Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference

Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease, announced today that Robert Baltera, Chief Executive Officer, will present a company overview at the Thomas Weisel Partners Healthcare Conference. The presentation is scheduled for 8:35 a.m. EDT on Wednesday, September 9, 2009, at The Four Seasons Hotel in Boston.

Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference

SAN DIEGO, - Amira Pharmaceuticals, Inc. announced today that it will present preclinical data from its LPA1 receptor antagonist program on June 30, 2009 at the Federation of American Societies for Experimental Biology (FASEB) Summer Research Conference in Carefree, Arizona.

The LPA1 receptor is part of the Phosphatidic Acid/Lysophosphatidylcholine pathway, which among other things is associated with cell to cell communication. In recent studies, it has been shown to potentially play a role in fibrotic disease, specifically Idiopathic Pulmonary Fibrosis (IPF).

"Our data not only confirms that this pathway may play a role in fibrotic diseases such as IPF, but that we are well on our way to developing an orally available antagonist which could be studied in a human clinical setting," said Peppi Prasit, Ph.D., Chief Scientific Officer. "While a great deal of work remains on this program, we are particularly excited since we believe this could be a novel, first-in-class therapy."

Bob Baltera, Chief Executive Officer, added, "Our LPA1 program is particularly important for Amira. IPF is a specialty focused disease setting and presents the opportunity for Amira to develop a therapeutic through commercialization without the assistance of a strategic partner. Most importantly, IPF is a grievous disease with minimally effective therapeutic options for patients today."